JPS58113754A - Production of artificial carrier - Google Patents

Production of artificial carrier

Info

Publication number
JPS58113754A
JPS58113754A JP20986881A JP20986881A JPS58113754A JP S58113754 A JPS58113754 A JP S58113754A JP 20986881 A JP20986881 A JP 20986881A JP 20986881 A JP20986881 A JP 20986881A JP S58113754 A JPS58113754 A JP S58113754A
Authority
JP
Japan
Prior art keywords
carrier
soln
gelatin
solution
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP20986881A
Other languages
Japanese (ja)
Other versions
JPS6332147B2 (en
Inventor
Mikio Ikeda
池田 幹雄
Takayuki Tomizawa
富沢 孝之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Priority to JP20986881A priority Critical patent/JPS58113754A/en
Priority to EP19820301235 priority patent/EP0062968B2/en
Publication of JPS58113754A publication Critical patent/JPS58113754A/en
Publication of JPS6332147B2 publication Critical patent/JPS6332147B2/ja
Granted legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548Carbohydrates, e.g. dextran
    • GPHYSICS
    • G03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03CPHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00Photosensitive materials
    • G03C1/005Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471Isoelectric point of gelatine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

PURPOSE:To obtain a carrier suited for serodiagnosis, etc. by contg. anionic or nonionic surfactants into a soln. contg. gelatin, water soluble polysaccharides, sodium polymetaphosphate as well as a hydrophilic org. solvent and water prior to adjusting of said soln. to a specific pH range. CONSTITUTION:Prior to adjusting of a soln. contg. gelatin, water soluble polysaccharides such as gum arabic, sodium polymetaphosphate (NaPO3)n, a hydrophilic org. solvent such as lower alcohol or aceton, and water to 2.5-6.0pH by adding acids under stirring at temp. higher than the gelling temp. of the gelatin, a soln. of anionic or nonionic surfactants is added thereto, then acids such as acetic acid soln. are added thereto to form gel particles. A particle dispersion is cooled and when the temp. thereof drops to <=10 deg.C, aldehyde crosslinking agents (glutaraldehyde, H2CO, etc.) are added to the soln. to obtain crosslinked gells. Thus, optional grain sizes can be provided to the carrier, and the homogeneous and stable carriers is obtained in good yields. The carrier bound with antigens or antibodies retains the initial characteristics without deterioration even when frozen abd preserved for a long period of time.

Description

【発明の詳細な説明】 定などに広く利用しうる新規な人工担体の製造方法の改
良に関する。抗原、抗体反応を利用する臨床検査等の分
野において、抗原まだは抗体をある適当な大きさの粒子
を担体とし−てそれに吸着もしくは結合させ、それ゛ぞ
れに対応する抗体または抗原の存在によってこの感作さ
れだ担体の凝集を起させる方法は間接受身凝集反応と呼
ばれている。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an improvement in a method for producing a novel artificial carrier that can be widely used in medicine and the like. In fields such as clinical testing that utilize antigen and antibody reactions, antigens and antibodies are adsorbed or bonded to particles of a certain appropriate size as carriers, and the presence of the corresponding antibody or antigen is used as a carrier. This method of causing aggregation of the sensitized carrier is called indirect passive agglutination reaction.

そして、この間接受身凝集反応は被検液中の抗体や抗原
を高感度に検出できるので、いろいろの疾患の血清学的
診断に広く用いられている。
Since this indirect passive agglutination reaction can detect antibodies and antigens in a sample liquid with high sensitivity, it is widely used for serological diagnosis of various diseases.

この反応に用,いられる担体としては、ポリスチレンラ
テックス、カオリン、炭末などの非生物学的粒子と、動
物赤血球、細菌菌体のような生物学的粒子とがあ・る。
The carriers used in this reaction include non-biological particles such as polystyrene latex, kaolin, and charcoal powder, and biological particles such as animal red blood cells and bacterial cells.

一般に非生物学的粒体の担体は、化学的に安定で、それ
自身抗原活性を有しないなどの利点はあるが、抗原ある
いは抗体が密に吸着されにくいという欠点がある。たと
えば、保存のために凍結乾燥すると抗原や抗体が担体か
ら遊離してしまうのである。そのために、やむなく液体
中で冷暗所に保存するという手段がとられているが、そ
の結果長期間保存することができない。また、非生物学
的担体のうち、炭末とカオリンは一定の大きさの粒子を
選出することが困難であ抄、ポリスチレンラテックスは
反応の媒質として望ましい中性域では非特異凝集である
自然凝集をおこす危険がある。
In general, non-biological particulate carriers have advantages such as being chemically stable and having no antigenic activity themselves, but have the disadvantage that antigens or antibodies are difficult to adsorb closely. For example, when freeze-drying for storage, antigens and antibodies are released from the carrier. For this reason, it is unavoidable to store it in a liquid in a cool, dark place, but as a result, it cannot be stored for a long period of time. In addition, among non-biological carriers, charcoal powder and kaolin are difficult to select particles of a certain size, and polystyrene latex is preferable as a reaction medium due to its natural aggregation, which causes non-specific aggregation in the neutral region. There is a risk of causing

一方、生物学的担体である動物赤血球や細菌菌体はそれ
ぞれの大きさが一定であるという利点はあるものの、生
物の種類によって粒子の大きさは定まっており、目的に
応じた任意の大きさの粒子を得ることはできなり0たと
えば、動物赤血球は大きさの一定した最も入手しゃすい
担体であるが、血球表面に固有の抗原を有しており、抗
体との間で非特異凝集反応である交差反応を起こして目
的とする凝集反応に誤まりを与える可能性がある。
On the other hand, although animal red blood cells and bacterial cells, which are biological carriers, have the advantage of having a fixed size, the particle size is fixed depending on the type of organism, and they can be of any size depending on the purpose. For example, animal red blood cells are the most readily available carrier with a constant size, but they have unique antigens on the surface of blood cells and can cause non-specific agglutination reactions with antibodies. There is a possibility that a certain cross-reaction may occur and the desired agglutination reaction may be erroneously determined.

さらに、赤血球の生物学的、化学的および物理的特性値
が動物の個体間でばらついてしまって常に一定品質の血
球を入手することが難しいという欠点がある。
Another disadvantage is that the biological, chemical, and physical properties of red blood cells vary among individual animals, making it difficult to obtain blood cells of constant quality.

本発明者らはこれらの欠点のないすぐれた担体を開発す
べく種々検討の結果、ゼラチン、水溶性□ 多糖類、およびポリメタリン酸ナトリウムを含み、水と
アルコール等の混合物を溶媒とする溶液を攪拌下で一調
整することによって粒子を析出させ、この粒子をアルデ
ヒド系架橋剤で処理して不溶化すれば、従来の欠点を尽
く解消したすぐれた担体が得られることを見出し、この
内容を既に特許出願した。この方法においては生成した
粒子の凝集を防止するために一調整後に界面活性剤を添
加していたが、本発明者らはその後さらに研究を進めた
結果、界面活性剤を一調整前に添加すれは担体の収量が
大巾に増加することを見出し、これに基いて本発明を完
成する忙到った。、tなわち本発明は、ゼラチン、水溶
性多糖類、ポリメタリン酸ナトリウム、親水性有機溶媒
、および水を含み、温度がゼラチンのゲル化温度以上で
ある溶液を、攪拌しつつ酸を加えてpH2,5〜6.0
に調整し、その後アルデヒド系架橋剤を作用せしめて不
溶化する人工担体の製造方法において、前記の一調整を
行なうまえに陰イオン系または非イオン系の界面活性剤
を前記溶液に含有させておくことを特徴とする人工担体
の製造方法に関するものである。
As a result of various studies in order to develop an excellent carrier that does not have these drawbacks, the present inventors discovered that a solution containing gelatin, a water-soluble polysaccharide, and sodium polymetaphosphate was stirred using a mixture of water, alcohol, etc. as a solvent. We discovered that by precipitating particles by making one adjustment below, and insolubilizing these particles by treating them with an aldehyde-based crosslinking agent, an excellent carrier that overcomes all the drawbacks of the conventional ones can be obtained, and we have already filed a patent application for this content. did. In this method, a surfactant was added after the first adjustment to prevent agglomeration of the generated particles, but as a result of further research by the present inventors, it was found that the surfactant was added before the first adjustment. found that the yield of the carrier was greatly increased and, on this basis, proceeded to complete the present invention. , t That is, in the present invention, a solution containing gelatin, a water-soluble polysaccharide, sodium polymetaphosphate, a hydrophilic organic solvent, and water and having a temperature equal to or higher than the gelation temperature of gelatin is adjusted to pH 2 by adding an acid while stirring. ,5~6.0
In the method for producing an artificial carrier in which the carrier is made insolubilized by the action of an aldehyde crosslinking agent, an anionic or nonionic surfactant is added to the solution before the above adjustment. The present invention relates to a method for producing an artificial carrier characterized by the following.

本発明に使用するゼラチンは通常は市販品をそのまま用
いればよい。市販品のなかでは酸性ゼラチンが好ましい
As the gelatin used in the present invention, commercially available gelatin may generally be used as is. Among commercially available products, acidic gelatin is preferred.

水溶性多糖類は増粘剤または糊料として使用しうるもの
であり、多糖類の誘導体および塩も含まれる。例として
は、アラビアゴム、カルボキシメチルセルロース、アル
ギン酸ナトリウム、寒天、カラダーナンなどを挙げるこ
とができるが、特にアラビアゴムが好適である。
Water-soluble polysaccharides can be used as thickeners or thickeners, and also include derivatives and salts of polysaccharides. Examples include gum arabic, carboxymethyl cellulose, sodium alginate, agar, caladanan, and gum arabic is particularly preferred.

ポリメタリン酸ナトリウムは化学式(NaPo5)nで
表わされる物質であり、たとえば四メタリン酸ナトリウ
ム、ヘキサメタリン酸ナトリウムの如きものである。
Sodium polymetaphosphate is a substance represented by the chemical formula (NaPo5)n, such as sodium tetrametaphosphate and sodium hexametaphosphate.

親水性有機溶媒としては、低級アルコール、たと、tt
f/チルアルコール、エチルアルコール、クロビルアル
コール等、およびア七トンなどを用いることができる。
Examples of hydrophilic organic solvents include lower alcohols, tt
f/tyl alcohol, ethyl alcohol, clobyl alcohol, etc., a7tone, etc. can be used.

そのほかのものとしては、担体を着色する場合には、着
色剤を粒子形成前に溶液に加えておくのがよい。着色を
必要とする例としては、本発明品を間接受身凝集反応の
担体として用いる場合を挙げることができる。すなわち
、本発明品は通常は無色不透明であるところから、これ
を着色することによって凝集像の判定を容易にすること
ができる。着色剤としては、たとえば食用赤色3号、ロ
ーダミン、ローズベンガル、/メソ−3R,yl?ルド
ーS1フクシン、エオシン、および二ミートラルレッド
などの赤色色素、あるいはクリスタルバイオレット、ト
ルイジンブルーおよびメチジ/ブルーなどの青色色素等
を用いうる。しかしながら、リアクティ!・レッド、ダ
イレクト・ブルーなどの反応性染料で着色すれば色落ち
しないことから、反応性染料が特に好適である。着色剤
以外にも目的に応じ種々の物質を添加してもよいことは
いうまでもない。
Alternatively, if the carrier is to be colored, a coloring agent may be added to the solution before particle formation. An example where coloring is required is when the product of the present invention is used as a carrier for an indirect passive aggregation reaction. That is, since the product of the present invention is normally colorless and opaque, by coloring it, the agglomerated image can be easily determined. Examples of coloring agents include Food Red No. 3, Rhodamine, Rose Bengal, /Meso-3R,yl? Red dyes such as Ludo S1 fuchsin, eosin, and dimetral red, or blue dyes such as crystal violet, toluidine blue and methidium/blue, and the like may be used. However, Reacti! - Reactive dyes such as red and direct blue are particularly suitable because the color will not fade if colored with reactive dyes. It goes without saying that in addition to the coloring agent, various substances may be added depending on the purpose.

一調整前の溶液におけるこれら各物質の濃度としては、
ゼラチ10.01〜2−程度、好ましくは0.05〜1
.0%程度、水溶性多糖類0.01〜2チ程度、好まし
くは0.05〜1.0’j程度、そして親水性有機溶媒
は4〜25容量優程度である。/’Jメタリン酸ナトリ
ウムはゼラチン乾燥重量の3〜15%程度を含有させる
ようKするのがよい。各物質はこれらの濃度範囲におい
て、所望の粒子の粒径および物性に応じて適宜定めれば
よい。着色剤を添加する場合には、゛通常は0.005
〜0.5チ程度であるが、反応性染料を用すればゼラチ
ン乾燥重置の1〜5チ程度で足りる。
The concentration of each of these substances in the solution before adjustment is as follows:
Gelatin: about 10.01 to 2, preferably 0.05 to 1
.. The water-soluble polysaccharide content is about 0.01 to 2 volumes, preferably about 0.05 to 1.0'j, and the hydrophilic organic solvent is about 4 to 25 volumes. /'J Sodium metaphosphate is preferably added in an amount of about 3 to 15% of the dry weight of gelatin. Each substance may be appropriately determined within these concentration ranges depending on the particle size and physical properties of the desired particles. When adding a colorant, it is usually 0.005
-0.5 inch, but if a reactive dye is used, about 1 to 5 inch of gelatin drying is sufficient.

本発明においては、このような溶液に一調整前にさらに
陰イオン系または非イオン系の界面活性剤を含有させる
ところに特徴がある。
The present invention is characterized in that an anionic or nonionic surfactant is further added to such a solution before adjustment.

陰イオン系界面活性剤の例としては、アルキルスルホコ
ハク酸、アルキルスルホマレイン酸、アルキル硫酸ニス
プル、ポリオキシェチレンアルキルエーテル硫酸エステ
ルなど、そして非イオン系界面活性剤の例としては、ポ
リオキシエチレン脂肪酸エステル、ポリオキ、シェチレ
/アルキルエーテル、、t?lJオキンエチレンアルキ
ルフェニルエーテル、ポリエチレングリコール脂肪酸エ
ステルなどを挙げることができる。界面活性剤は粒子の
凝集を防止する目的で添加するのであるが、陽イオン系
の界面活性剤では粒子の凝集を防止することができない
ので本発明の対象外である。声調整前の容液における濃
度としては、陰イオン系界面活性剤の場合は0.001
〜0.01%程度、非イオン系界面活性剤の場合は0.
01〜0.1チ程度で凝集防止効果が得られる。溶液を
冷却すればもっと低い濃度で凝集を防止することができ
る。
Examples of anionic surfactants include alkyl sulfosuccinic acids, alkyl sulfomaleic acids, Nispur alkyl sulfates, polyoxyethylene alkyl ether sulfates, and examples of nonionic surfactants include polyoxyethylene fatty acids. Ester, polyoxy, Chetyle/alkyl ether, t? Examples include lJ oquin ethylene alkylphenyl ether and polyethylene glycol fatty acid ester. Surfactants are added for the purpose of preventing particle aggregation, but cationic surfactants cannot prevent particle aggregation and are therefore outside the scope of the present invention. The concentration in the liquid before voice adjustment is 0.001 for anionic surfactants.
~0.01%, and 0.01% for nonionic surfactants.
Agglomeration prevention effect can be obtained at about 0.01 to 0.1 inch. Agglomeration can be prevented at lower concentrations by cooling the solution.

このような溶液を調製する過程は問うところではなく、
例えば各々を温水に溶解してから混合してもよく、各々
を一緒に溶解してもよい。しかしながら、各物質の溶解
を容易忙するために親水性有機溶媒はあとから加えるの
がよく、また水溶性多糖類には不溶成分も少量含まれて
いることが多いところから、別途に溶解して添加するの
がよい。
The process of preparing such a solution is not in question;
For example, each may be dissolved in warm water and then mixed, or each may be dissolved together. However, in order to facilitate the dissolution of each substance, it is best to add the hydrophilic organic solvent later, and since water-soluble polysaccharides often contain small amounts of insoluble components, they must be dissolved separately. It is good to add it.

一方、ゼラチンは等電点以下の−゛では水溶性多糖類と
反応して白濁を生ずるので酸性ゼラチンを用いる場合に
はアルカリを加えて溶液の−を少なくともその付近Kま
で高めておくのがよい。しかしながら、とΩ白濁は生じ
た後でもアルカリを添加することによって消すことがで
きる。いずれにせよ、溶液は酸の添加を開始するまえK
は白濁のなハ状態にしておかなければならない。
On the other hand, gelatin reacts with water-soluble polysaccharides at temperatures below its isoelectric point, producing cloudiness, so when using acidic gelatin, it is best to add an alkali to raise the solution's temperature to at least around that point. . However, even after opacity has occurred, it can be eliminated by adding alkali. In any case, the solution is K before starting the acid addition.
must be kept in a cloudy state.

溶液の温度はゼラチンのrル化温度以上でなけれげなら
ない。この温度はゼラチンの濃度等によって異なるが通
例25〜30℃程度である。良好な粒子形成の観点から
特に35〜50℃程度がよい。
The temperature of the solution must be above the gelatin's gelatinization temperature. This temperature varies depending on the concentration of gelatin, etc., but is usually about 25 to 30°C. From the viewpoint of good particle formation, the temperature is particularly preferably about 35 to 50°C.

次に、この溶液を攪拌しながら酸を加えて−2,5〜6
.0に調整する。この工程は粒子を生成させるところで
ある。均一な粒子を形成させるために、35〜50 U
K加温を続け、適度に攪拌しながら酸を滴下していくの
がよい。pH2,5〜6.0の範囲における至適の−は
原料溶液の組成および目的とする粒径によって異なるの
で予め実験を行なって定めるのがよい。たとえば得られ
た粒子を抗原感作用担体に用いる場合には2〜10μ程
度の粒径にするのがよく、その場合至適の−は4.0〜
5.5の範囲にある。との−調整釦使用する酸は特に限
定されるものではなく無機酸でも有機酸でもよいが、な
るべくおだやかなものがよく、たとえば酢酸などが好適
である。
Next, add acid to this solution while stirring and add -2,5 to 6
.. Adjust to 0. This step is where particles are generated. 35-50 U to form uniform particles
It is best to continue heating and add the acid dropwise while stirring moderately. The optimum value within the range of pH 2.5 to 6.0 varies depending on the composition of the raw material solution and the intended particle size, so it is best to determine it by conducting experiments in advance. For example, when the obtained particles are used as an antigen-sensitizing carrier, the particle size is preferably about 2 to 10 μm, and in that case, the optimum − is 4.0 to 10 μm.
It is in the range of 5.5. The acid to be used is not particularly limited and may be an inorganic acid or an organic acid, but it is preferably as mild as possible, and for example, acetic acid is preferred.

本[程で生成した粒子は系の温度をゼラチンのデル化温
度以下に下げても消失しないので母液との平衡関係はな
い。また、ゼラチンと水溶性多糖類との混合比にもよる
が、粒子はほとんどの場合正に帯電しており、その表面
にはポリメタリン酸イオンが配向していていわゆる電気
二重層を形成している。そして、このことが粒♀の安定
な分散を促しているのである。
The particles produced in this process do not disappear even if the temperature of the system is lowered below the delification temperature of gelatin, so there is no equilibrium relationship with the mother liquor. Furthermore, although it depends on the mixing ratio of gelatin and water-soluble polysaccharide, the particles are almost always positively charged, and polymetaphosphate ions are oriented on their surfaces, forming a so-called electric double layer. . This also promotes stable dispersion of the female particles.

酸の添加後は生成した粒子の凝集を防止するために速か
に粒子分散液を冷却するのがよい。そして、液温か10
℃以下になったところでアルデヒド系架橋剤を添加して
粒子を不溶化する。この架橋剤の添加量はゼラチン乾燥
重量の0,1〜200チ程度であり、添加後は一夜程度
放置して架橋反応を充分に行なわせる。架橋剤の例とし
ては、グルタルアルデヒド、ホルムアルデヒド、グリオ
キザール、クロトンアルデヒド、アクロレイン、アセト
アルデヒドなどを挙げることができるが、特にグルタル
アルデヒドが好適である。
After adding the acid, it is preferable to quickly cool the particle dispersion to prevent the formed particles from agglomerating. And the liquid temperature is 10
When the temperature drops below 0.degree. C., an aldehyde crosslinking agent is added to insolubilize the particles. The amount of this crosslinking agent added is about 0.1 to 200 inches of the dry weight of gelatin, and after addition, the mixture is left to stand overnight to allow the crosslinking reaction to occur sufficiently. Examples of the crosslinking agent include glutaraldehyde, formaldehyde, glyoxal, crotonaldehyde, acrolein, and acetaldehyde, with glutaraldehyde being particularly preferred.

アルデヒド系架橋剤で処理後は粒子を遠心分離等で回収
して、必要により洗浄する。洗浄は粒子分散のために用
°いた界面活性剤と同じものを同濃度で含む水で2〜3
回行なえばよい。
After treatment with the aldehyde crosslinking agent, the particles are collected by centrifugation or the like, and washed if necessary. Washing is done with water containing the same surfactant at the same concentration as the one used for particle dispersion.
Just go around.

このようにして得られた担体を種々の用途に供すればよ
いが、架橋が不充分な場合には塩類溶液中で膨潤するこ
とがある。そこでこのような用途に用いる場合にはアル
デヒド系架橋剤で処理して膨潤を防止するのがよい。例
えば、抗原を感作する場合にはリン酸緩衝液中で行なう
ので、赤血球を固定化する条件でホルマリン処理する。
The carrier thus obtained may be used for various purposes, but if crosslinking is insufficient, it may swell in a salt solution. Therefore, when used for such purposes, it is recommended to treat with an aldehyde crosslinking agent to prevent swelling. For example, when sensitizing an antigen, it is carried out in a phosphate buffer, so formalin treatment is performed under conditions that fix red blood cells.

この処理によって膨潤を防止するとともにホルマリンの
殺菌効果によって長期間の保存に耐える担体が得られる
This treatment prevents swelling and provides a carrier that can withstand long-term storage due to the sterilizing effect of formalin.

本発明の担体は抗原、抗体、酵素などを巾広く固定する
ことができる。たとえば、抗原とか抗体を感作する場合
には動物赤血球を担体として行な最もすぐれているとさ
れていた一物赤血球と同等な性能を有し、さらに化学的
、物理的に均質かつ安定であり、抗原活性がなく任意の
粒径のものを容易かつ安価に大量生産できるなど動物赤
血球にない幾多の利点を有するものである。そして、本
発明は先願発明に比し、界面活性剤の添加時期を変える
ことによって担体の収率を大巾に高めている。
The carrier of the present invention can immobilize a wide variety of antigens, antibodies, enzymes, and the like. For example, when sensitizing antigens or antibodies, animal red blood cells are used as carriers, which have the same performance as the best single red blood cells, and are chemically and physically homogeneous and stable. It has many advantages over animal red blood cells, such as no antigenic activity and the ability to easily and inexpensively mass-produce particles of any particle size. In addition, the present invention greatly increases the yield of the carrier by changing the timing of addition of the surfactant as compared to the prior invention.

以下、実施例及び担体の使用例を示す。なお、本明細書
において、チは特に記載がなければ重量%を表わしてい
る。
Examples and usage examples of carriers are shown below. In this specification, unless otherwise specified, q represents weight %.

実施例1 等電点がPH9であるゼラチン4tを40℃の温水に1
001/になるように溶解し、10チの水酸化ナトリウ
ム溶液を用いてpH9に調整した。アラビアゴム4tを
100m/になるように水に溶解し、不溶物をr別しだ
後40℃に加温した。
Example 1 4 tons of gelatin with an isoelectric point of pH 9 was added to 40°C hot water.
The solution was dissolved to a pH of 0.001% and adjusted to pH 9 using 10% sodium hydroxide solution. 4 tons of gum arabic was dissolved in water to a concentration of 100 m/g, and after removing insoluble matter, the solution was heated to 40°C.

このようにして得られたゼラチン溶液59m/とアラビ
アゴム溶液501/を混合し、この混合液をあらかじめ
40℃に加温した30容量係のメチルアルコール溶液3
0.0 II/に注ぎ入れ、よく攪拌した。これに10
チヘキサメタリン酸ナトリウム溶液1.6II7!、1
チアルキルスルホマレイン酸(商品名デモールE、)溶
液2I1111および1チダイレクトブルー溶液5 m
lを加えてよく攪拌した。
59ml of the gelatin solution obtained in this way and 50ml of the gum arabic solution were mixed, and this mixed solution was heated to 40°C in advance to form a 30 volume methyl alcohol solution.
0.0 II/ and stirred well. 10 for this
Sodium thihexametaphosphate solution 1.6II7! ,1
Thialkyl sulfomaleic acid (trade name Demol E) solution 2I1111 and 1T direct blue solution 5 m
1 was added and stirred well.

次いで、40℃に保ちながら10容量チの酢酸′溶液を
滴下してp)14.8に調整し、粒子を生成させた。
Next, while maintaining the temperature at 40°C, 10 volumes of acetic acid' solution was added dropwise to adjust the p) to 14.8 to form particles.

この−調整によって得られた粒子分散液を水冷して5℃
にしてからゲルタールアルデヒド1.32を加え、よく
攪拌後との温度で一夜静置した。それからこの粒子分散
液を200 Orpmで10分間遠心分離して粒子を4
レツトとして回収した。この粒子を0.005%デモー
ルE溶液に懸濁して遠心分離する洗浄操作を3回繰返し
てから、4容量チホルマリン溶液に分散し、5℃で1週
間放置した。
The particle dispersion obtained by this adjustment was cooled with water to 5°C.
Then, 1.32 g of geltaraldehyde was added, and after stirring well, the mixture was allowed to stand overnight at the same temperature. The particle dispersion was then centrifuged at 200 rpm for 10 minutes to remove the particles.
It was collected as a lettuce. A washing operation in which the particles were suspended in a 0.005% Demol E solution and centrifuged was repeated three times, then dispersed in 4 volumes of thiformin solution and left at 5° C. for one week.

本例で得られた担体粒子は7.7?であり、千の75m
が3〜6μの範囲にあった。
The carrier particles obtained in this example were 7.7? And 75m of 1,000
was in the range of 3 to 6μ.

実施例2 3o容tsのメチルアルコール溶液のカワリニにして担
体粒子を調製した。但し、酢酸を滴下して調製したーは
449であった。こうして得られた担体粒子は7.8t
であり、その70%が7〜11μの範囲にあった。
Example 2 Carrier particles were prepared by diluting 30 volumes of methyl alcohol solution. However, the value of - prepared by dropping acetic acid was 449. The carrier particles thus obtained were 7.8 tons.
, and 70% of them were in the range of 7 to 11μ.

実施例3 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 3 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、まずアラビアゴム4tのかわりにカルデキシ
メブルセルロース1tを、そして30容量チのメチルア
ルコール溶液のかわりに30容量チエチルアルコール溶
液を用いた。それから、添加量についても、ゼラチン、
10 %へキサメタリン酸ナトリウム溶液、1チデモー
ルE、溶液、1esダイレクトブルー溶液、およびグル
タルアルデヒドをいずれも4分の1にした。また、−も
4.8から4.6にした。
That is, first, 1 ton of caldeximable cellulose was used instead of 4 tons of gum arabic, and 30 volumes of ethyl alcohol solution was used instead of 30 volumes of methyl alcohol solution. Also, regarding the amount added, gelatin,
The 10% sodium hexametaphosphate solution, 1thidemol E, solution, 1es Direct Blue solution, and glutaraldehyde were all reduced to one quarter. In addition, - was also increased from 4.8 to 4.6.

このようにして得られた担体粒子は3.8tであり、そ
の90%が1〜2μの範囲にあった。
The carrier particles thus obtained were 3.8t, 90% of which were in the range of 1-2μ.

実施例4 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 4 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、ゼラチン溶液を50m1から40m1にし、
アラビアゴム溶液を501nlから60m1に変えた。
That is, the gelatin solution was increased from 50 ml to 40 ml,
The gum arabic solution was changed from 501 nl to 60 ml.

それから、1・0チヘキサメタリン酸ナトリウム溶液を
l、 5 yslから1.2 mlに、1チダイレクト
プルー溶液を6 yslから4.8mlに、そしてグル
タルアルデヒドを1.32から1.OyKそれぞれ変え
た。
Then, 1.0 sodium thihexametaphosphate solution was added from 5 ysl to 1.2 ml, 1 thidirect pull solution was added from 6 ysl to 4.8 ml, and glutaraldehyde was added from 1.32 to 1.2 ml. I changed each OyK.

また、酢酸滴下終了−を4.6とした。Moreover, the end of acetic acid addition was set at 4.6.

本例で得られた担体粒子は6.42であり、その90チ
が1〜2μの範囲にあった。
The carrier particles obtained in this example had a particle size of 6.42, and 90 particles were in the range of 1 to 2μ.

実施例5 下記の点を除いて実施例1と同様にして担体粒子を調製
した。
Example 5 Carrier particles were prepared in the same manner as in Example 1 except for the following points.

すなわち、ゼラチン溶液を50m1から60dにしアラ
ビアゴム溶液を50m1から40rnlに変えた。
That is, the gelatin solution was changed from 50 ml to 60 d, and the gum arabic solution was changed from 50 ml to 40 rnl.

それから、10%へキサメタリン酸ナトリウム溶液をl
、 5 ttrlから2mlに、1係リアクテイブレツ
ド6履tを1チダイレクトブル−7.2 mlに、そし
てグルタルアルデヒドを1.32から1.82にそれぞ
れ変えた。iた、酢酸滴下終了−を4.8とした。
Then add l of 10% sodium hexametaphosphate solution.
, the amount of glutaraldehyde was changed from 1.32 to 1.82. The completion of acetic acid addition was set at 4.8.

本例で得られた担体粒子の収量は8.6fであり得られ
た粒子の75チが3〜6μの範囲にあった。
The yield of carrier particles obtained in this example was 8.6f, and 75 particles of the obtained particles were in the range of 3 to 6μ.

使用例1 実施例1で得られた担体粒子を、下表 に示す濃度のタ
ンニン酸を含むPH7,2のリン酸塩緩衝生理食塩水(
以下、PBSと略記する。)中に粒子濃度が2.5チに
なるように分散し、37℃で15分間加温した。粒子を
遠心分離して生理食塩水で充分洗浄した。
Use Example 1 The carrier particles obtained in Example 1 were mixed with phosphate buffered saline (pH 7.2) containing tannic acid at the concentration shown in the table below.
Hereinafter, it will be abbreviated as PBS. ) and heated at 37° C. for 15 minutes. The particles were centrifuged and thoroughly washed with saline.

梅毒病原体トレポネーマ・バリーダム(以下、TPと略
記する。)菌体をP)(6,4のPBS中に浮遊させ超
音波で菌体を破壊してTP抗抗原色した。
Bacterial cells of the syphilis pathogen Treponema ballidum (hereinafter abbreviated as TP) were suspended in PBS (P)(6,4), and the cells were destroyed using ultrasound and TP anti-antigen coloring was performed.

前記のタンニン酸処理粒子をPBSに5%の濃度に分散
し、この分散液を下表に示す倍数で希釈したTPP原液
と等容づつ混合した。混合液を37℃で40分間加温し
て、粒子に、TP抗原を感作した。
The tannic acid-treated particles were dispersed in PBS at a concentration of 5%, and this dispersion was mixed in equal volumes with the TPP stock solution diluted in the multiples shown in the table below. The mixture was heated at 37° C. for 40 minutes to sensitize the particles to the TP antigen.

TPP原感作粒子を遠心分離して−6,4のPBSで充
分洗浄し、分散用メディウムに濃度が5−になるように
分散した。
The TPP original sensitized particles were centrifuged, thoroughly washed with -6.4 PBS, and dispersed in a dispersion medium to a concentration of 5-.

このようにして得られたTPP原感作粒子分散液を用い
、マイクログレート法で梅毒陽性血清と反応させたとこ
ろ下表に示す如き結果が得られた。
When the TPP original sensitized particle dispersion thus obtained was reacted with syphilis-positive serum by the micrograte method, the results shown in the table below were obtained.

なお、対照としてヒツノ赤血球を担体に用いた場合の結
果もあわせて下表に示す。
As a control, the results obtained when human red blood cells were used as a carrier are also shown in the table below.

使用例2 実施例1で得られた担体粒子をタンニン酸10ppmを
含む−7,2のPBS中に粒子濃度が2.5チになるよ
うに分散し、37℃で15分間加温した。
Use Example 2 The carrier particles obtained in Example 1 were dispersed in -7.2 PBS containing 10 ppm of tannic acid to a particle concentration of 2.5 cm, and heated at 37°C for 15 minutes.

粒子を遠心分離して生理食塩水で充分洗浄し、lチにな
るようにpH7,2のPBS中に分散した。一方、高純
度に精製したストレプトキナーゼをpH7,2のPBS
 K 128 UAIになるように溶解した。
The particles were centrifuged, thoroughly washed with physiological saline, and dispersed in PBS, pH 7.2, to a uniform volume. On the other hand, highly purified streptokinase was added to PBS at pH 7.2.
It was dissolved to give K 128 UAI.

タンニン酸処理粒子分散液4 mlとストレプトキナー
ゼ溶液4 mlとを混合し、37℃で30分間加温した
。その後、粒子を遠心分離してpH7,2のPBSで洗
浄し、粒子濃度1%になるようにpH7,5のゼラチン
緩衝液に分散した。なお、ゼラチン緩衝液はゼラチン5
1.塩化ナトリウム101、およびリン酸カリウム13
.61を1!に溶解したものである。
4 ml of the tannic acid-treated particle dispersion and 4 ml of the streptokinase solution were mixed and heated at 37° C. for 30 minutes. Thereafter, the particles were centrifuged, washed with PBS, pH 7.2, and dispersed in gelatin buffer, pH 7.5, to a particle concentration of 1%. In addition, the gelatin buffer solution is gelatin 5
1. Sodium chloride 101, and potassium phosphate 13
.. 61 to 1! It is dissolved in

この粒子分散液のストレプトキナーゼ活性は約60Uで
あったので、溶液中の酵素の約12チが粒子に固定され
たことになる。
Since the streptokinase activity of this particle dispersion was about 60 U, this means that about 12 units of the enzyme in the solution were immobilized on the particles.

酵素活性の測定方法は次のように行なった。すなわち、
酵素溶液または粒子分散液0.25 mlにヒトプラズ
マQ、 l tnlおよびトロンビン溶液0.05 m
lを加えて37℃で30分間加温した。トロンビン溶液
は500単位のトロンビンをホウ酸緩衝液で80倍に希
釈したものである。酵素活性は、線装置を阻止するスト
レプトキナーゼの最大希釈倍数で示した。
The enzyme activity was measured as follows. That is,
0.05 ml of human plasma Q, l tnl and thrombin solution to 0.25 ml of enzyme solution or particle dispersion
1 was added and heated at 37°C for 30 minutes. The thrombin solution is 500 units of thrombin diluted 80 times with borate buffer. Enzyme activity was expressed as the highest dilution of streptokinase that inhibited the line apparatus.

特許出願人 富士臓器製薬株式会社 代理人 弁理士 1)中 政 浩Patent applicant: Fuji Organ Pharmaceutical Co., Ltd. Agent Patent Attorney 1) Masahiro Naka

Claims (1)

【特許請求の範囲】[Claims] ゼンチノ、水溶性多糖類、ポリメタリン酸ナトリウム、
親水性有機溶媒、および水を含み、温度がゼラチ/のケ
゛ル化温度以トである溶液を、攪拌しつつ酸を加えてp
H2,5〜6oに調整し、その後アルデヒド系架橋剤を
作用せしめて不溶化する人り担体の製造方法において、
前記の一調整を行なうまえに陰イオン系または非イオン
系の界面活性剤を前記溶液に含有させておくことを特徴
とする人工担体の製造方法。
Zentino, water-soluble polysaccharide, sodium polymetaphosphate,
A solution containing a hydrophilic organic solvent and water and having a temperature equal to or higher than the gelatinization temperature is heated by adding an acid while stirring.
In a method for producing a human carrier, the carrier is adjusted to H2,5 to 6o, and then treated with an aldehyde crosslinking agent to make it insolubilized.
A method for producing an artificial carrier, characterized in that an anionic or nonionic surfactant is added to the solution before the above adjustment.
JP20986881A 1981-03-18 1981-12-28 Production of artificial carrier Granted JPS58113754A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP20986881A JPS58113754A (en) 1981-12-28 1981-12-28 Production of artificial carrier
EP19820301235 EP0062968B2 (en) 1981-03-18 1982-03-11 Support material for use in serological testing and process for the production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20986881A JPS58113754A (en) 1981-12-28 1981-12-28 Production of artificial carrier

Publications (2)

Publication Number Publication Date
JPS58113754A true JPS58113754A (en) 1983-07-06
JPS6332147B2 JPS6332147B2 (en) 1988-06-28

Family

ID=16579958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20986881A Granted JPS58113754A (en) 1981-03-18 1981-12-28 Production of artificial carrier

Country Status (1)

Country Link
JP (1) JPS58113754A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084626A1 (en) * 2009-01-20 2010-07-29 ベックマン コールター,インコーポレイテッド Method for detection of presence of anti-platelet antibody

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084626A1 (en) * 2009-01-20 2010-07-29 ベックマン コールター,インコーポレイテッド Method for detection of presence of anti-platelet antibody

Also Published As

Publication number Publication date
JPS6332147B2 (en) 1988-06-28

Similar Documents

Publication Publication Date Title
US4416813A (en) Artificial carrier for immobilization of biological proteins
Gibbons et al. Synthesis of extracellular dextran by cariogenic bacteria and its presence in human dental plaque
KR100321665B1 (en) Chitin beads, chitosan beads, processes for producing these beads, carriers made of these beads and processes for producing microsprodidian spores
US3242051A (en) Coating by phase separation
JPS6038655A (en) Granular reagent for immunoassay
JPS5858145A (en) Microcapsule with fast releasability and preparation thereof
EP0424975B1 (en) Artificial carrier for immobilization of biological proteins and process for production thereof
CN109044963A (en) A kind of injection pH sensitivity nano-hydrogel and preparation method thereof
JPS5951355A (en) Reagent for detecting antiviral antibody
Hobson et al. Some studies on the identification of rumen bacteria with fluorescent antibodies
JPH0317103B2 (en)
JP2859343B2 (en) Process for producing free-flowing spray-dried edible powder comprising oil
US3584113A (en) Process for the production of medical preparations having sustained release of therapeutical effect
EP0129619B1 (en) Encapsulated cells, their method of preparation and use
JPS58113754A (en) Production of artificial carrier
JPH0317303B2 (en)
EP0062968B2 (en) Support material for use in serological testing and process for the production thereof
SU784879A1 (en) Method of obtaining brucellosis erythrocytic diagnosticum
JPS58113757A (en) Manufacture of artificial carrier
JPS5935143A (en) Carrier for immobilizing actic protein
JPS6332148B2 (en)
JPS58113756A (en) Production of artificial carrier
JPS6329223B2 (en)
JPS6332146B2 (en)
Itagaki et al. Volume phase transition of chemically cross-linked curdlan hydrogels dependent on pH

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term
S199 Written request for registration of transfer of right

Free format text: JAPANESE INTERMEDIATE CODE: R313199

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370